AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ATRA · NASDAQ · Biotechnology

Atara Biotherapeutics

Supports Pierre Fabre’s global EBV-targeted tab-cel program through a lean partner-led operating model.

$9.20

After-hours close+0.07 (+0.77%)

At close$9.13(−1.30%)

Something off on this page? Send us feedback.

Profile

Atara Biotherapeutics, Inc.ATRAHealth Care

Supports Pierre Fabre’s global tab-cel program after transferring most related operating activities. Its lean partner-led model depends on the BLA resubmission process, milestones and royalties, and funding operations.

Built around allogeneic, Epstein–Barr virus-targeted T-cell therapies, the business now supports Pierre Fabre’s global tab-cel, also called EBVALLO, program. The arrangement replaced a broader independent drug-development model with a partner-led operation.

Pierre Fabre holds development, manufacturing, commercialization and BLA sponsorship responsibilities after the transfer of substantially all tab-cel activities and associated costs. Atara continues to support the partner while evaluating strategic alternatives.

Its remaining model depends on the partner-controlled U.S. resubmission process, resolution of FDA and manufacturing issues, potential milestones and royalties under the Pierre Fabre agreement, and its ability to fund operations.

Company facts

CEOAnhCo "Cokey" Nguyen, Ph.D.

ListedOct 16, 2014

ExchangeNASDAQ

HeadquartersThousand Oaks, CA

CountryUnited States

Employees13

CIK0001604464

ISINUS0465132068

Key statistics

Market cap$82.9M

EPS (ttm)−$1.18

P/E (ttm)−7.80

ROE44.7%

P/B−3.74

P/S13.38

Dividend yield—

Beta1.29vs XLV 1.14

Year to date −48.6% · Average volume (30d) 50.5K

Analysts

Price target, next 12 months$13.00+41.3%Median of 13 analysts · vs the Aug 28 close

ConsensusHold4 of 13 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $9.20

High$13.00+41.3%

Median$13.00+41.3%

Low$13.00+41.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
May 18, 2026	Freedom Broker	Upgrade	Sell	Hold
May 8, 2026	Canaccord Genuity	Upgrade	Hold	Buy	$25	$13
Jan 21, 2026	Freedom Broker	Downgrade	Buy	Sell
Jan 13, 2026	New Street	Target				$6
Jan 13, 2026	Canaccord Genuity	Downgrade	Buy	Hold

Earnings

EPS

Estimate−$0.14

ReportedDue Nov 11, 2026

Revenue

Estimate$1.0M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	−$0.32	−$0.32	−1.6%	$550.0K	$630.0K	+14.5%	−7.80%
Aug 11, 2026Q2 FY26	−$0.32	−$0.32	−1.6%	$550.0K	$630.0K	+14.5%	+3.24%
May 12, 2026Q1 FY26	−$0.33	−$0.29	+12.0%	$2.9M	$516.0K	−82.2%	+6.83%
Mar 16, 2026Q4 FY25	−$0.09	−$0.25	−177.8%	$3.4M	$1.6M	−51.2%	−10.90%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$98.1M	$17.6M	$3.5M	$1.6M	$516.0K	$630.0K
Gross profit	$77.7M	$17.0M	$3.3M	$1.5M	$392.0K	$439.0K
Operating income	$38.8M	$3.2M	−$3.6M	−$2.6M	−$3.4M	−$4.7M
Net income	$38.0M	$2.4M	−$4.3M	−$3.4M	−$4.1M	−$4.8M
Diluted EPS	$3.50	$0.19	−$0.32	−$0.25	−$0.29	−$0.32
Gross margin	79.2%	96.8%	96.7%	93.5%	76.0%	69.7%
Operating margin	39.5%	18.2%	-103.5%	-160.7%	-652.9%	-749.2%

Fiscal years (4-quarter sums)FY21 $20.3M · FY22 $63.6M · FY23 $8.6M · FY24 $128.9M · FY25 $120.8M

Balance sheet, Jun 30, 2026Cash & short-term investments $9.9M · Total debt $9.9M · Total assets $21.0M · Shareholders' equity −$37.0M

Dividends

No dividends on record.

Ownership

Institutions 49.59%4.47M sharesInsiders 26.23%2.36M sharesOther 24.18%2.18M shares

Shares outstanding 9.01M · Float 6.00M · 66.6% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Ecor1 Capital, LLC	1.55M	17.22%	13F	Aug 14, 2026
Adiumentum Capital Fund I LP · director, 10 percent owner, other: See remarks	1.21M	13.42%	Form 4	May 16, 2025
Panacea Innovation Ltd · 10 percent owner	1.01M	11.22%	Form 4	May 11, 2026
Adage Capital Partners GP, L.L.C.	850.0K	9.43%	13F	Aug 14, 2026
Point72 Asset Management, L.P.	687.7K	7.63%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 17, 2026	AnhCo Nguyen	director, officer: President and CEO	−5,062	$8.08
May 18, 2026	Yanina Grant-Huerta	officer: Chief Accounting Officer	−2,414	$9.13
May 18, 2026	AnhCo Nguyen	director, officer: President and CEO	−5,241	$9.13
May 7, 2026	EcoR1 Capital, LLC	10 percent owner	+507,407	$9.35
May 7, 2026	Panacea Innovation Ltd	10 percent owner	−313,446	$10.10